Rapastinel alleviates the neurotoxic effect induced by NMDA receptor blockade in the early postnatal mouse brain

Eur Arch Psychiatry Clin Neurosci. 2021 Dec;271(8):1587-1591. doi: 10.1007/s00406-020-01180-5. Epub 2020 Aug 13.

Abstract

Rapastinel is a novel psychoactive substance that acts as an N-methyl-D-aspartate-receptor (NMDAR) agonist and triggers antidepressant- and antipsychotic-like effects in animal models. However, it is unknown if rapastinel possesses a better side-effect profile than fast-acting glutamatergic antidepressants, like ketamine, which trigger neurotoxicity in the perinatal rodent cortex and protracted schizophrenia-like alterations. Here we found a remarkable neuroprotective effect of rapastinel against apoptosis induced by the NMDAR antagonist MK-801 in comparison to that elicited by clozapine and the mGlu2/3 agonist LY354740. These results suggest the potential therapeutic/prophylactic effect of rapastinel in ameliorating deleterious effects induced by NMDAR blockade during neurodevelopment.

Keywords: Antipsychotic drug; Caspase-3; MK-801; Neuroprotection; Neurotoxicity; Rapastinel.

MeSH terms

  • Animals
  • Cerebral Cortex* / metabolism
  • Mice
  • Neuroprotective Agents* / pharmacology
  • Oligopeptides* / pharmacology
  • Receptors, N-Methyl-D-Aspartate* / antagonists & inhibitors
  • Receptors, N-Methyl-D-Aspartate* / metabolism

Substances

  • Neuroprotective Agents
  • Oligopeptides
  • Receptors, N-Methyl-D-Aspartate
  • GLYX-13 peptide